Medroxyprogesterone Acetate Pfizer (Medroxyprogesterone Acetate)

Medroxyprogesterone Acetate acts on the hormonal axis to provide contraceptive and therapeutic benefits in several gynecologic conditions.

• Contraception: Provides effective hormonal birth control by suppressing ovulation.
• Menstrual disorder management: Regulates irregular cycles and reduces heavy bleeding.
• Endometriosis treatment: Limits ectopic endometrial growth and associated pain.
• Menopause hormone replacement therapy: Replaces declining progesterone to alleviate menopausal symptoms.
• Prevention of endometrial hyperplasia: Protects the uterine lining when combined with estrogen.

• Medroxyprogesterone Acetate binds to progesterone receptors, acting as an agonist. This activation suppresses the hypothalamic‑pituitary‑gonadal axis, reducing luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) release, which prevents ovulation. In target tissues, it induces endometrial transformation, creating a secretory environment that opposes estrogen‑driven proliferation.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Weight gain: Increased appetite or fluid retention.
• Headache: Mild to moderate intensity.
• Breast tenderness: Discomfort or swelling of breast tissue.
• Nausea: Stomach upset, sometimes with vomiting.
• Irregular bleeding: Spotting or breakthrough bleeding.
• Mood changes: Irritability or depressive symptoms.

Serious or Rare Side Effects

• Thromboembolic events: Deep vein thrombosis or pulmonary embolism.
• Severe allergic reaction: Rash, swelling, or anaphylaxis.
• Liver dysfunction: Jaundice or elevated liver enzymes.
• Depression or suicidal thoughts: New or worsening mood disorders.
• Adrenal suppression: Signs of cortisol deficiency.

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

• Cardiovascular risk assessment: Review history of thrombosis, hypertension, or smoking.
• Liver function monitoring: Check baseline enzymes and repeat as needed.
• Cancer screening: Exclude hormone‑sensitive malignancies.
• Smoking cessation counseling: Advise patients to stop smoking to reduce thrombotic risk.
• Drug interaction review: Verify concomitant medications that may affect hormone metabolism.
• Store at room temperature: Keep in original packaging, protect from moisture and direct sunlight.

Medroxyprogesterone Acetate can alter or be altered by other medicines; careful management is required.

Major Interactions (Avoid)

• Combined estrogen therapy: Increases risk of thromboembolism.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): May raise plasma levels.
• Anticoagulants (e.g., warfarin): Heightened bleeding risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin): May reduce effectiveness.
• Antiepileptic drugs (e.g., carbamazepine): Potentially lower hormone concentrations.
• Glucocorticoids: May enhance adrenal suppression.